Trials / Completed
CompletedNCT02338128
The Cardiovascular Protective Effects of Febuxostat in Peritoneal Dialysis Patients
The Cardiovascular Protective Effects of Febuxostat in Peritoneal Dialysis Patients: a Prospective Cohort Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (actual)
- Sponsor
- Shanghai 10th People's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether Febuxostat could protect cardiovascular function of peritoneal dialysis patients by lowering serum uric acid.
Detailed description
Patients with more than 3-month-history of peritoneal dialysis and hyperuricemia. Use Febuxostat to control their serum uric acid for 1 year. To observe the cardiovascular events of patients, and compare and evaluate the changes of heart function, heart construction, serum cardiac markers and brain natriuretic peptide (BNP) levels before and after Febuxostat treatment.
Conditions
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2018-01-01
- Completion
- 2018-01-01
- First posted
- 2015-01-14
- Last updated
- 2019-07-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02338128. Inclusion in this directory is not an endorsement.